11th May 2005 06:00
Pfizer Statement on Status of Bextra NEW YORK, May 10 -- In response to media inquiries, Pfizer today issued the following statement: As previously communicated, Pfizer has suspended sales of Bextra (valdecoxib) pending further discussions with the U.S. Food and Drug Administration (FDA). Pfizer continues to believe that Bextra could be an important treatment option for certain patient populations. In the future, the company plans to discuss options with the FDA under which Bextra might be made available to those patients. SOURCE Pfizer Inc 05/10/2005 /CONTACT: Mariann Caprino, +1-212-733-4554, for Pfizer Inc/ /Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html/ /Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888./ /Company News On-Call: http://www.prnewswire.com/comp/688250.html / /Web site: http://www.pfizer.com / (PFE) ENDPFIZER INCRelated Shares:
PFZ.L